1. Scrip

How The IRA Factored Into Akebia’s Price For Vafseo

CSL Vifor Deal Converted To Royalty Agreement

 
• By Alaric DeArment

Akebia said it had set the price for Vafseo at about $15,500 per year, meant to reflect its potential value in dialysis as well as eventually in non-dialysis patients.

• Source: Shutterstock

A lot went into Akebia Therapeutics, Inc.’s decision to price its chronic kidney disease (CKD) drug, Vafseo (vadadustat), at $1,278 per month, but the Inflation Reduction Act (IRA) and its impact on drug pricing were certainly part of it.

The Cambridge, MA-based company said 11 July that it had given Vafseo a wholesale acquisition cost (WAC) of about $15,500 per patient per year based on the starting dose of...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Drug Pricing

More from Scrip

Quick Listen: Scrip’s Five Must-Know Things

 
• By Ian Haydock

In this week's episode: Novo Nordisk’s CEO forced out; quantifying biopharma’s contribution to the US economy; a history of MASH deals; lift for AstraZeneca’s asthma ambitions; and major Japanese firms see US revenue growth.

Ascentage Broadens Horizons As Pipeline Shows Renewed Promise

 
• By Xu Hu

Ascentage will share at ASCO new clinical data on its Bcl-2 inhibitor lisaftoclax, part of the Chinese firm's novel pipeline, on which its CEO shared with Scrip plans and strategy, along with some views on the use of RWD in China.

Tech Convergence, Quality Data Needed To Accelerate Korea’s AI-Powered R&D

 
• By Jung Won Shin

AI-powered drug development was a major topic at the recent Bio Korea meeting, where experts discussed how the technology is changing R&D activities and the challenges being faced by Korean firms as they look to catch up with their global competitors.